Correction to: Development and validation of a modified albumin–bilirubin grade and α-fetoprotein score (mALF score) for hepatocellular carcinoma patients receiving atezolizumab and bevacizumab (Hepatology International, (2023), 17, 1, (86-96), 10.1007/s12072-022-10406-8)

On behalf of the Real-life Practice Experts for HCC (RELPEC) Study Group, and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan)

Research output: Contribution to journalComment/debate

1 Scopus citations

Abstract

The Figs. 2 and 3 were erroneously labeled in the original publication of the article. ‘ALF score’ should be corrected as ‘mALF score’. The Figs. 2 and 3 should have appeared as shown below.

Original languageEnglish
Pages (from-to)271-273
Number of pages3
JournalHepatology International
Volume17
Issue number1
DOIs
StatePublished - 2023/02

ASJC Scopus subject areas

  • Hepatology

Fingerprint

Dive into the research topics of 'Correction to: Development and validation of a modified albumin–bilirubin grade and α-fetoprotein score (mALF score) for hepatocellular carcinoma patients receiving atezolizumab and bevacizumab (Hepatology International, (2023), 17, 1, (86-96), 10.1007/s12072-022-10406-8)'. Together they form a unique fingerprint.

Cite this